George W Sledge Jr. MD

Oncology•Stanford, CA

Professor of Medicine, Indiana University

Join to View Full Profile

300 Pasteur DrStanford, CA 94305
Phone+1 650-723-4000
Fax+1 650-498-5840

Education & Training

University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 1981 - 1983
SSM Health/Saint Louis University School of MedicineResidency, Internal Medicine, 1977 - 1980
Tulane University School of MedicineClass of 1977

Certifications & Licensure

CA State Medical License 2013 - 2026
IN State Medical License 1983 - 2013
LA State Medical License 1977 - 1983
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2 Start of enrollment: 1999 Aug 01
Completed
Phase 2
Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer Start of enrollment: 2003 Jun 06
Completed
Phase 3
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer Start of enrollment: 2005 Sep 01
Terminated
Quality of Life in Female Breast Cancer Survivors and Their Spouse, Partner, or Acquaintance Start of enrollment: 2006 Apr 03
Completed
Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer Start of enrollment: 2006 Oct 01
Completed
Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer Start of enrollment: 2007 Sep 01
Terminated
Lonafarnib in Metastatic Breast Cancer Start of enrollment: 2008 Oct 01
Terminated
Phase 2
Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer Start of enrollment: 2009 Aug 01
Terminated
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
ACTIVE_NOT_RECRUITING
PHASE3
4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer Start of enrollment: 2017 Oct 30
Completed
Phase 1
Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer Start of enrollment: 2020 Oct 13
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

A 20-feature radiomic signature of triple-negative breast cancer identifies patients at high risk of death.
Humaira Noor, Yuanning Zheng, Adam B Mantz, Ryle Zhou, Andrew Kozlov
NPJ Breast Cancer. 2025-07-26
3 citations
Characterization of Plasma Cell-Free DNA Variants as of Tumor or Clonal Hematopoiesis Origin in 16,812 Advanced Cancer Patients.
Daniel Magee, Valeriy Domenyuk, Jim Abraham, Nieves Perdigones Borderias, Jeff Swensen
Clinical Cancer Research. 2025-07-01
Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers.
Arielle L Heeke, Andrew Elliott, Kaitlyn O'Keefe, Chad Livasy, James T Symanowski
JCO Precision Oncology. 2025-01-01

Lectures

The 15th International Symposium on Anti-Angiogenic Therapy: Recent Advances and Future Directions in Basic and Clinical Care Research
The University of Texas, M. D. Anderson Cancer Center, San Diego, California - 1/31/2013

Press Mentions

Tailoring Treatment: Real-World Evidence Guides ADC Sequencing in Breast CancerSeptember 18th, 2025
ImmixBio Announces Dr. George W. Sledge of Stanford University Medical Center Joins Scientific Advisory BoardAugust 9th, 2021
Susan G. Komen® Announces 30 New Grants to Advance Discovery in Critical and Emerging Areas of Breast Cancer ResearchJune 30th, 2021
Join now to see all